-
Pangaea Data Secures Strategic Investment from Topcon Healthcare, Inc. to Close Global Care Gaps in Eye Health
SOUTH SAN FRANCISCO, CA; LONDON, UK; and LA JOLLA, CA – Pangaea Data, a health AI company specializing in identifying untreated and under-treated patients at scale, today announced a strategic investment from Topcon Healthcare, Inc., a global leader in ophthalmic medical devices and digital health solutions. The collaboration aims to accelerate the application of Pangaea’s clinically validated AI platform to address critical care gaps in eye health and systemic disease.Pangaea Data’s platform automatically analyzes structured and unstructured patient records against clinical guidelines, emulating a clinician’s manual review, to uncover patients who meet diagnostic or treatment criteria, but are not currently in a treatment or management process. Integrated directly into existing EHR and downstream scheduling systems, the platform enables real-time clinical action without disrupting workflows.“We are thrilled to partner with Topcon Healthcare to scale our platform’s reach and improve timely diagnosis and treatment across eye care,” said Dr. Vibhor Gupta, Founder and CEO of Pangaea Data. “Together, we can empower providers to close care gaps while generating actionable insights for population health, discovery science, and value-based care.”Through this partnership, Pangaea Data’s AI platform will leverage Topcon Healthcare’s Harmony® digital health platform, creating a seamless interface for optometry and ophthalmology practices to identify patients needing follow-up or further evaluation. This includes patients with conditions such as glaucoma, 50% of whom remain undiagnosed in the U.S.1, and diabetic retinopathy, where more than one-third of diagnosed diabetics do not receive their recommended annual eye screening2.“Pangaea Data’s unique ability to find missed patients using AI, and to do so without burdening clinicians, has powerful implications for eye care and beyond,” said Ali Tafreshi, CEO & President of Topcon Healthcare, Inc. “This partnership supports our Healthcare from the Eye™ initiative, which uses ocular data and AI to transform how systemic and ocular diseases are detected and managed. We are proud to support Pangaea Data’s mission through this strategic investment.”Pangaea Data’s platform has already demonstrated impact across multiple therapeutic areas, including pulmonology, cardiology, oncology, nephrology, and infectious diseases. The company’s expansion into eye care through this partnership represents a significant step in advancing AI-driven clinical care globally.1 Current Glaucoma Programs | Vision and Eye Health | CDC – https://www.cdc.gov/vision-health/php/glaucoma-programs/index.html2 Diabetic Retinopathy Screening – EyeWiki – https://eyewiki.org/Diabetic_Retinopathy_ScreeningAbout Pangaea DataPangaea Data provides an AI platform that is configured on clinical guidelines to mimic and therefore automate a clinician’s manual process for finding untreated (undiagnosed, misdiagnosed, miscoded, at-risk, uncontrolled) and under-treated patients with hard-to-diagnose conditions for screening and treatment at the point of care. These patients may otherwise be missed, despite information available in their health records, due to treatment for other conditions or administrative reasons. Pangaea’s platform is designed to be deployed behind the healthcare provider’s firewall, without moving data, facilitating privacy compliance. Furthermore, the platform is designed to seamlessly integrate with existing EHR systems, avoiding disruption to existing clinical or IT workflows. Pangaea Data’s founders, Dr. Vibhor Gupta and Prof. Yike Guo, have over 20 years of academic and industry experience. Their advisors and investors include industry veterans, such as Lord David Prior (Former Chairman, NHS England) and Mr. Andy Palmer (Former Head of Systems Integration, Novartis). For more information, visit www.pangaeadata.aiAbout Topcon Healthcare, Inc.Topcon Healthcare, Inc. is part of Topcon Corporation, a leading provider of digital healthcare solutions. Our vision is to improve access and quality of healthcare while decreasing the cost of care. To achieve this vision, we created Healthcare from the Eye™, a connected care ecosystem using AI-powered disease detection and management applied to noninvasive retinal imaging.
-
Moorfields Eye Hospital, UCL Institute of Ophthalmology and Topcon Healthcare, Inc. launch Cascader Limited to advance AI-driven eyecare and Oculomics
Moorfields Eye Hospital NHS Foundation Trust, the UCL Institute of Ophthalmology (IoO), and Topcon Healthcare today announced the launch of Cascader Limited, a new medical technology company that aims to transform the detection and management of eye disease through artificial intelligence (AI). Cascader also builds on the growing field of Oculomics – the use of advanced retinal imaging to uncover insights into systemic conditions such as cardiovascular disease, neurodegeneration, and dementia.Cascader represents a strategic partnership between world-leading academic and clinical institutions and a global healthcare technology provider. The company combines the pioneering AI research and translational expertise of Moorfields and UCL IoO with the technical capabilities and international reach of Topcon Healthcare, a provider of ophthalmic imaging systems used in hospitals and community clinics around the world. UCL Business (UCLB), the commercialisation company for UCL and its partner hospitals, was also instrumental in the set-up of the new venture.Headquartered in London, Cascader is focused on accelerating the translation of cutting-edge AI from research into real-world clinical tools – so that novel diagnostic technologies can reach patients faster.Its initial focus will be on macular diseases such as age-related macular degeneration (AMD), a leading cause of irreversible vision loss that affects one in eight people over the age of 60. This builds on landmark work led by Moorfields and UCL IoO, including the 2016 collaboration with Google DeepMind and the development of RETFound, the first foundation model in ophthalmology, published in Nature in 2023.Cascader’s long-term mission is to develop a portfolio of AI tools to support earlier and more accurate detection of disease across the full spectrum of eye care – from high-street optometry to hospital-based specialist clinics – and to further advance Oculomics as a foundation for precision medicine.Cascader will be supported by the INSIGHT Health Data Research Hub, the world’s largest ophthalmic imaging bioresource, led by Moorfields. INSIGHT comprises over 35 million retinal images linked to clinical metadata and enables secure, anonymised data access for approved researchers – supported by advanced AI infrastructure, curation services, and active patient involvement.Cascader marks a significant step in translating Oculomics into clinical care and aligns with broader global efforts – including Topcon Healthcare’s Healthcare from the Eye™ initiative – to harness ocular data as a gateway to more proactive, connected, and equitable healthcare.Peter Ridley, Chief Executive of Moorfields Eye Hospital:“We are proud to support the founding of Cascader. This new venture represents the next step in our commitment to translating world-class clinical research into tangible benefits for patients and the NHS.”Ali Tafreshi, Chief Executive Officer, Topcon Healthcare:“Topcon is thrilled to partner with Moorfields and the UCL Institute of Ophthalmology on this groundbreaking initiative. Cascader reflects our shared vision of how AI and ocular data can reshape eyecare and enable new frontiers in precision medicine. This collaboration supports the broader mission of connecting ocular data to better health outcomes – both within eyecare and beyond.”Mark Fisher, Associate Director at UCLB:“UCLB is delighted to have played a role in the establishment in this new company alongside Moorfields Eye Hospital NHS Foundation Trust and Topcon Inc. Partnering with industrial leaders in the new area of oculomics should accelerate routes to market for AI technologies and break down the barriers of AI applications in healthcare. It exemplifies the benefits of close relationships between academics and clinicians in creating technologies that will bring major benefits to patients as a result of earlier diagnosis in a range of diseases.”Professor Pearse Keane, Chief Medical Advisor and co-founder of Cascader; consultant ophthalmologist at Moorfields Eye Hospital; professor of artificial medical intelligence at UCL IoO:“Cascader is uniquely positioned at the intersection of clinical excellence, academic leadership, and technological innovation. We are building on more than a decade of research into AI and Oculomics – fields in which we’ve been proud to lead globally – and are now focused on delivering those discoveries into everyday clinical care.”Dr. Peter Thomas, Chief Executive Officer and co-founder of Cascader; consultant ophthalmologist at Moorfields Eye Hospital:“We have a huge opportunity to reshape how eye care is delivered by bringing AI to frontline services – whether in hospitals, clinics, or the high street. Cascader will play a key role in translating groundbreaking research into real-world tools that support both patients and professionals.”Ege Ilicak, Chief Operating Officer and co-founder of Cascader:“At Cascader, our mission is to turn cutting-edge research into clinically robust, scalable solutions that improve lives. With deep experience in medical engineering, we’re focused on ensuring that our AI-driven tools meet the highest quality and regulatory standards, while integrating seamlessly into real-world workflows—supporting professionals and empowering patients.” For further information, please contact moorfields.pressoffice@nhs.net or Leslie Amodei at lamodei@amaeharaAbout Cascader’s founding team:Cascader’s founding team brings together deep expertise across the clinical, technical, and operational spectrum:• Professor Pearse Keane, a global leader in ophthalmic AI and Oculomics, has led pioneering research at Moorfields and UCL IoO, including co-inventing RETFound, the world’s first foundation model in ophthalmology, and extensive work defining the field of Oculomics.• Dr Peter Thomas, brings extensive experience in developing and delivering innovative healthcare services powered by technology, leading digital transformation programmes, and holding executive and national leadership roles within the NHS. • Ege Ilicak, chief operating officer, brings 15 years of experience in the medical engineering field, from hands-on software development to managing large-scale projects and building quality management systems to bring healthcare innovations successfully to market.About Moorfields Eye Hospital NHS Foundation TrustMoorfields Eye Hospital NHS Foundation Trust is one of the leading providers of eye health services in the UK and a world class centre of excellence for ophthalmic research and education. Our main focus is the treatment and care of NHS patients with a wide range of eye problems, from common complaints to rare conditions that require treatment not available elsewhere in the UK. Our unique patient case mix and the number of people we treat mean that our clinicians have expertise in discrete ophthalmic sub-specialties.We treat people in 20 locations in and around London, the south east and Bedford, enabling us to provide expert treatment closer to patients’ homes. We also operate commercial divisions that provide care to private patients in both London and the Middle East. With our academic partners at the UCL Institute of Ophthalmology, Moorfields is recognised as a leading centre of excellence in eye and vision research. Together we form one of the largest ophthalmic research sites in the world, with the largest patient population in Europe or the USA. We publish more scientific papers than any other eye and vision research site and have an extensive joint research portfolio.About UCL Institute of OphthalmologyThe UCL Institute of Ophthalmology is one of a number of specialised research centres within UCL (University College London) and is, together with Moorfields Eye Hospital, one of the leading centres for eye research worldwide. The combination of the institute’s research with the resources of Moorfields Eye Hospital opens the way for advances at the forefront of vision research. Close collaboration with other academic partners and with industry extends its impact. The institute has been named as the best place to study ophthalmology in the 2017 Centre for World University Rankings (CWUR). For further information, please visit www.ucl.ac.uk. Follow @ucleye on Twitter.About UCL (University College London)UCL is a diverse global community of world-class academics, students, industry links, external partners, and alumni. Our powerful collective of individuals and institutions work together to explore new possibilities.Since 1826, we have championed independent thought by attracting and nurturing the world’s best minds. Our community of more than 50,000 students from 150 countries and over 16,000 staff pursues academic excellence, breaks boundaries and makes a positive impact on real world problems.The Times and Sunday Times University of the Year 2024, we are consistently ranked among the top 10 universities in the world and are one of only a handful of institutions rated as having the strongest academic reputation and the broadest research impact.We have a progressive and integrated approach to our teaching and research – championing innovation, creativity and cross-disciplinary working. We teach our students how to think, not what to think, and see them as partners, collaborators and contributors. For almost 200 years, we are proud to have opened higher education to students from a wide range of backgrounds and to change the way we create and share knowledge.We were the first in England to welcome women to university education and that courageous attitude and disruptive spirit is still alive today. We are UCL.www.ucl.ac.uk | Read news at www.ucl.ac.uk/news/ | Follow UCL News on Bluesky and LinkedInAbout Topcon Healthcare, Inc.Topcon Healthcare, Inc. is part of Topcon Corporation, a leading provider of digital healthcare solutions. Our vision is to improve access and quality of healthcare while decreasing the cost of care. To achieve this vision, we created Healthcare from the Eye™, a connected care ecosystem using AI-powered disease detection and management applied to noninvasive retinal imaging.About the INSIGHT Health Data Research HubINSIGHT is the world’s largest ophthalmic imaging bioresource, with over 35 million eye images linked to clinical data. An NHS initiative led by Moorfields in partnership with University Hospitals Birmingham, INSIGHT makes routinely collected patient eye data available for approved research that could lead to improvements in diagnosis, care and treatment of eye diseases, as well as systemic disease such as stroke and Alzheimer’s. INSIGHT’s mission is to improve healthcare by making it simpler for researchers to use large, anonymised sets of patient data in a safe and ethical way.
-
EYE-GO Secures Strategic Investment from Topcon Healthcare to Drive the Future of Connected Eye Care
COPENHAGEN, DENMARK & LA JOLLA, CA, USA — EYE-GO, a pioneering Danish MedTech company specializing in next-generation ophthalmic drug delivery, today announced a strategic investment from Topcon Healthcare, Inc., a global leader in robotic diagnostics and digital health solutions. This partnership aligns with Topcon Healthcare’s mission to improve access to high-quality eye care while reducing overall healthcare costs. The collaboration reflects a shared vision to revolutionize chronic eye disease management by integrating drug delivery, real-world adherence data, and diagnostic insights into a single, connected care pathway.“We are thrilled to welcome Topcon Healthcare as a strategic investor and partner,” said Christian Stig Møller, Chairman of EYE-GO. “In Topcon Healthcare, we’ve found not only a leading force in eyecare technology, but also a visionary partner in the digital health space. This strategic partnership also strengthens the EYE-GO board of directors with the appointment of Ali Tafreshi, Topcon Healthcare, Inc. CEO & President, and Robert N. Weinreb, MD, Distinguished Professor of Ophthalmology, University of California, San Diego.”This partnership will accelerate the development of the MistGo® Digital – a first-in-class microdosing drug delivery system combined with a digital adherence monitoring platform. The system reminds patients to administer their medication, verifies correct usage, and transmits real-time adherence data to clinicians. By combining precision drug delivery with intelligent monitoring, MistGo Digital closes the critical gap between prescription, administration, and compliance.“MistGo Digital is a breakthrough in ophthalmic therapy—bridging the gap between prescription and practice,” said Henrik Nagel, CEO of EYE-GO. “Topcon Healthcare’s involvement validates our approach and brings strategic synergy that will help realize our vision of fully connected eye care – from diagnostics to ongoing therapy management.”As a part of the collaboration, MistGo Digital will be integrated into Topcon Healthcare’s Harmony® digital health information platform. This integration will enable clinicians to link adherence and administration data with imaging results and disease progression, fostering earlier interventions and highly personalized care strategies.“Digital technology is transforming eye care, and MistGo Digital represents a leap forward in how therapies are delivered and monitored,” said Ali Tafreshi, CEO of Topcon Healthcare, Inc. “EYE-GO’s innovation complements our vision of connected care pathways. Adding an intelligent therapeutic solution enhances the patient experience, improves outcomes, and supports a more data-driven future for eye care.”This strategic partnership places both companies at the forefront of a growing movement toward connected health in eye care – where smart devices, data insights, and remote monitoring work together to optimize clinical care and elevate patient outcomes.About EYE-GO A/SEYE-GO is a MedTech innovation company dedicated to improving outcomes in eye health through advanced ophthalmic drug delivery. Its flagship solution, MistGo®, eliminates the complexity of traditional eye drops and is now evolving into MistGo Digital – the first connected platform that enables both reminder functionality and confirmation of medication use, providing valuable insight to patients, caregivers, and clinicians alike.In a recently conducted user survey¹ with the flagship solution, MistGo®, 20 out of 22 respondents expressed a preference for MistGo® over traditional eye drop bottles.¹ Manuscript in preparation; not yet peer-reviewed or publishedAbout Topcon Healthcare, Inc.Topcon Healthcare, Inc. is part of Topcon Corporation (TSE 7732). We are a leading provider of digital healthcare solutions whose vision is to improve access and quality of healthcare while decreasing the cost of care. To achieve this vision, we created Healthcare from the Eye™, the strategy of applying AI models to imaging data from the eye to facilitate earlier detection and better management of disease. Healthcare from the Eye is powered by Harmony®, a cloud-based, vendor-inclusive digital health information platform enabling a connected care ecosystem.
-
Topcon Healthcare Launches IDHea™ to Fuel AI and Digital Health Innovation from the Eye
LA JOLLA, CA — Topcon Healthcare, Inc., a global leader in robotic diagnostics and digital health solutions, today announced the launch of the Institute of Digital Health (IDHea™), an ocular data-as-a-service platform designed to accelerate AI research and digital health innovation. IDHea provides fast and secure access to unique real-world and clinical trial datasets, driving breakthroughs in healthcare applications that improve outcomes in both ocular and systemic diseases. IDHea empowers researchers and innovators to push the boundaries of digital health solutions.Part of Topcon’s Healthcare from the Eye™ initiative, the strategy of applying AI models to imaging data from the eye to facilitate earlier detection and better management of disease, IDHea provides a platform to transform clinical data into actionable insights through AI-powered analytics and seamless connectivity. It was developed to unlock exclusive datasets and fuel digital health advancements. By bridging the gap between data and discovery, IDHea propels innovation toward a future of predictive, personalized, and proactive patient care.IDHea is built on the FAST principle, ensuring that data access is:Fast -providing rapid access to a vast repository of real-world and clinical trial ocular dataAccessible – data is available anytime, anywhere through a secure cloud-based infrastructureSafe– the platform adheres to industry-standard practices for privacy and security for a safe and trustworthy data environmentTransparent – each data request undergoes rigorous review by an independent data access and governance committee following established and publicly accessible policiesAdvancing AI-Powered DiagnosticsIDHea offers access to highly structured, multilevel-labeled datasets from primary care and eye care screening settings, encompassing both healthy individuals and a broad spectrum of eye conditions.“We established IDHea to accelerate development of AI-powered clinical decision support systems and oculomics, the science of analyzing ocular data to identify, diagnose, and manage ocular and systemic disease,” said Julia Coelho, VP of Data and Digital Strategy.Through the Topcon Healthcare Innovation Center (THINC), researchers also gain access to specialized expertise and resources that accelerate AI development and reduce time to market. These innovations can be commercialized and scaled for impact through Topcon Healthcare’s global footprint, leveraging the Harmony® digital health information platform.IDHea offers deeply phenotyped, real-world and clinical ocular data curated specifically for precision AI development. This includes high-resolution imaging, visual function metrics, and multimodal health data aligned with clinical outcomes—creating an unprecedented foundation for digital health innovation.Supported by strategic data partners—Illinois College of Optometry (ICO), Keplr Vision, New England College of Optometry (NECO), New View Optometric Center (NVOC), and Visionworks, IDHea launch is a significant milestone enhancing access to real-world ocular data, thereby facilitating meaningful research in digital healthcare.By providing a robust foundation for phenotyping healthy eye anatomy and studying deviations from this anatomy due to early disease manifestation, IDHea empowers researchers to advance AI-powered diagnostics and push the boundaries of digital health innovation.Empowering Innovation with Responsible Data SharingIDHea’s governance framework empowers responsible innovation through ethical, secure, and transparent data practices. At its core is an independent data access and governance committee, comprised of experts in medicine, technology, policy, and ethics, that oversees every data request to uphold fairness and accountability. IDHea’s transparent policies provide clear insight into how data decisions are made, with summaries shared for each fulfilled request to reinforce trust. Backed by a secure computing infrastructure and industry-leading de-identification protocols, IDHea protects privacy while enabling safe, impactful research. This commitment empowers scientific discovery while safeguarding the rights of data contributors.“Topcon Healthcare’s motivation to facilitate broad access to ocular data is an important first step towards accelerating data standardization,” said Anthony Khawaja, PhD, Chair of the independent data access and governance committee. “Such an initiative will significantly reduce the current limitations for innovation that the proprietary formats of ophthalmic data impose.” With IDHea, the future of ocular and systemic disease research is within reach. By leveraging data, we’re building a more connected and efficient global healthcare ecosystem.About Topcon Healthcare, Inc.Topcon Healthcare, Inc. is part of Topcon Corporation. We are a leading provider of digital healthcare solutions whose vision is to improve access and quality of healthcare while decreasing the cost of care. To achieve this vision, we created Healthcare from the Eye™, the strategy of applying AI models to imaging data from the eye to facilitate earlier detection and better management of disease. Healthcare from the Eye is powered by Harmony®, a cloud-based, vendor-inclusive digital health information platform enabling a connected care ecosystem. For more information about Topcon Healthcare, visit TopconHealthcare.com. More information about IDHea can be found at www.idhea.net.
-
Topcon Healthcare, Inc. Acquires RetInSight GmbH to Accelerate its AI-Powered Imaging Innovation in Eye Care
LA JOLLA, CA — Topcon Healthcare, Inc., a leading provider of medical devices and digital healthcare solutions, today announced the acquisition of RetInSight GmbH, a privately held company based in Vienna, Austria, renowned for its innovation in retinal imaging AI solutions. The move advances Topcon Healthcare’s vision of Healthcare from the Eye™, enhancing access to intelligent diagnostics that increase access to high-quality eye care, reduce healthcare costs, and improve clinical outcomes.RetInSight’s AI algorithms analyze optical coherence tomography (OCT) images captured in routine clinical care to detect and monitor major retinal diseases – geographic atrophy, neovascular age-related macular degeneration, diabetic macular edema, and retinal vein occlusion – which are the leading causes of vision loss globally. These tools enable earlier intervention and personalized treatment planning, especially for aging populations.“With Topcon Healthcare’s infrastructure, we can scale reliable and affordable AI software globally,” said Prof. Hans Peter Schwarz, Chairman of the Board of RetInSight. “This partnership supports clinical care, drug discovery, and therapeutic innovation worldwide.”RetInSight’s platform, born from pioneering research at the Medical University of Vienna, Department of Ophthalmology and Optometry, under the direction of Prof. Dr. Ursula Schmidt-Erfurth, is already commercialized throughout Europe and is vendor-inclusive supporting interoperability across multiple OCT systems.“RetInSight’s OCT-based AI expertise will help our global network of partners rapidly deploy innovations,” said Ali Tafreshi, CEO & President of Topcon Healthcare, Inc. “Integrated with our Harmony® vendor-inclusive digital information system, we’re delivering clinical decision support and a scalable ecosystem for AI deployment.”Already used in pharmaceutical trials, RetInSight’s algorithms also support AI-powered drug development and regulatory pathways, including advancing FDA clearances for U.S. indications. “Together, we’re enabling seamless patient monitoring across the eye care continuum,” said Dr. Amir Sadeghipour, Managing Director of RetInSight. “This collaboration brings intelligent care to patients anywhere.”This acquisition marks a pivotal step toward global AI adoption in eye care, fostering a connected, developer-friendly ecosystem that drives better outcomes worldwide. About RetInSight GmbHRetInSight GmbH, based in Vienna, was founded in 2020 with the ambition that longevity should not come at the expense of vision loss. We aim to enable people to maintain their full vision in order to preserve their quality of life and lifelong autonomy. We are therefore developing transformative AI-based software solutions that leverage routine optical coherence tomography (OCT) images to monitor and detect progressive retinal diseases such as geographic atrophy (GA), neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO) – the most important age-related diseases that lead to visual impairments in today’s world. Our mission is to revolutionize ophthalmology through reliable, affordable, and easy-to-use AI-based medical software that enables timely diagnosis, accurate monitoring, and personalized treatment of retinal diseases for anyone, any time and at any location by supporting networked care in ophthalmology with the help of AI technology and digital data. For more info, visit www.retinsight.comAbout Topcon Healthcare, Inc.Topcon Healthcare, Inc. is part of Topcon Corporation, a leading provider of digital healthcare solutions. Our vision is to improve access and quality of healthcare while decreasing the cost of care. To achieve this vision, we created Healthcare from the Eye™, a connected care ecosystem using AI-powered disease detection and management applied to noninvasive retinal imaging.
-
Topcon Healthcare Equips Indianapolis Motor Speedway with Latest in Vision Testing Solutions
September 17, 2024 | Topcon NewsShare on:.wp-social-link svg { fill: #fff !important; } .wp-block-columns .sns { padding: 0; text-align: right;}Topcon Healthcare is proud to align with the Infield Care Center, a state-of-the-art onsite medical facility, to support the visual health needs of drivers.INDIANAPOLIS, IN – Topcon Healthcare and Indianapolis Motor Speedway (IMS) announced this week IMS has acquired state-of-the-art ophthalmic solutions from Topcon. This equipment will benefit NTT INDYCAR SERIES and INDY NXT by Firestone drivers for their annual physicals and medical exams during race season. It also will be used on drivers, spectators and visitors when needed.Topcon Healthcare is a global leader in innovating digital healthcare solutions. As the primary partner of INDY NXT by Firestone driver James Roe, Topcon is part of the fabric of the motorsport community. Topcon Healthcare is proud to align with IMS to support the visual health needs of drivers.“As a driver traveling at speeds where the blink of an eye equals 50 to 100 feet of track surface, our eye health is critically important to success and safety,” said Roe. “I’m thrilled to see Topcon and IMS – two world leaders that mean so much to me – come together to ensure that the absolute best in vision testing technology is available to drivers like me and our industry at large.” The Topcon Healthcare solution includes a full eye examination suite as well as its NW500 retinal camera, Maestro2 OCT, CV-5000S Digital Phoropter, and TEMPO Perimeter. This comprehensive solution portfolio ensures IMS has the technology needed to provide cutting-edge onsite eye examination services.“Our support of IMS is aligned with our mission to increase access to best-in-class eyecare and healthcare services around the globe,” said Topcon Healthcare CEO and President Ali Tafreshi. “IMS drivers, crew and fans at IMS now have access to cutting-edge ophthalmic solutions. The safety and visual health of the drivers, crew, staff and fans is paramount, and we take immense pride in being part of this important mission.”The Topcon Healthcare equipment will be located within the IU Health Emergency Medical Center, where comprehensive driver physicals are performed. Treatment also is provided for spectators who experience minor injury or dehydration. The IU Health Emergency Medical Center is equipped and at-the-ready to handle the vast majority of health issues that arise at the track, including complex on-track trauma.“Topcon Healthcare really understands the importance of precision, timing and state-of-the-art technology in motorsports,” said IMS president J. Douglas Boles. “INDYCAR drivers are traveling the length of a football field in less than a second, so their eyes are critical. They have to look as far forward as possible and react quickly to what they see. Working with a company like Topcon Healthcare ensures our drivers are safe and competitive on track.”Roe and his Topcon-branded INDY NXT presented by Firestone car will make an appearance at the Topcon Healthcare booth at the 2024 American Academy of Ophthalmology meeting in October.About Topcon Healthcare, Inc.Topcon Healthcare, Inc. is part of Topcon Corporation (TSE 7732). We are a leading provider of digital healthcare solutions whose vision is to improve access and quality of healthcare while decreasing the cost of care. To achieve this vision, we created Healthcare from the Eye™, the strategy of applying AI models to imaging data from the eye to facilitate earlier detection and better management of disease. Healthcare from the Eye™ is powered by Harmony®, a cloud-based, vendor-inclusive digital health information platform enabling a connected care ecosystem.A truly global business, Topcon Corporation is focused on developing solutions to solve societal challenges in the mega domains of healthcare, agriculture, and infrastructure. In healthcare, these challenges include increasing eye disease, rising medical costs, physician shortages, and unequal access to healthcare. By investing in value-driven innovations, Topcon Corporation works to help people enjoy good health and a better quality of life.About IMSThe Indianapolis Motor Speedway, the world’s largest spectator sporting facility, has been the worldwide leader in motorsports entertainment since opening in 1909. IMS hosts the Indianapolis 500 presented by Gainbridge – the world’s most prestigious auto race. That race is the climax of an exciting Month of May schedule for the NTT INDYCAR SERIES that also includes the Sonsio Grand Prix on the IMS road course. NASCAR returns to the famous 2.5-mile oval during Brickyard Weekend, featuring the Brickyard 400 presented by PPG for the NASCAR Cup Series and Pennzoil 250 for the NASCAR Xfinity Series. The IMSA WeatherTech SportsCar Championship also returns to IMS for the TireRack.com Battle on the Bricks. Other events at IMS feature the NOS Energy Drink USAC National Midget Series, Intercontinental GT Challenge Powered by Pirelli and Sportscar Vintage Racing Association. IMS, the NTT INDYCAR SERIES and IMS Productions are owned by Penske Corporation, a global transportation, automotive and motorsports leader. To purchase tickets or for more information, please visit ims.com.
-
Topcon Healthcare Inc. partners with Microsoft to deliver AI-powered ‘Healthcare from the Eye’ through a connected healthcare platform
Topcon Healthcare Inc (THI) announces a partnership with Microsoft Corporation to deliver AI-powered ‘healthcare from the eye’ solutions to improve healthcare access, cost, and quality. A cloud-based connected network of healthcare providers using the Nuance Precision Imaging Network and the THI Harmony platform will empower patients and healthcare providers to participate in pre-screening for systemic and neurological disease via a robotic, rapid, and non-invasive eye scan. “We are committed to making healthcare accessible and affordable through pre-screening using oculomics-leveraging the eye for insights into systemic and neurological health. We call this, Healthcare from the Eye. A key element of this effort is Harmony – a vendor-inclusive, secure, connected data management platform,” said Ali Tafreshi, CEO & President of Topcon Healthcare Inc.To accelerate AI research and innovation for Healthcare from the Eye, THI established the Institute for Digital Health (IDHea). IDHea, a large, secure, population database platform, is governed by an external data access and governance (DAG) committee to ensure fair and ethical access to data. IDHea is engaged in multiple research studies with organizations including Visionworks and Keplr Vision integrating Microsoft Azure secure cloud-storage and advanced computing technologies to ensure data security and protect propriety algorithms. A proof-of-concept study involving National Vision Inc, Toku Inc, and BeeKeeperAI demonstrates that Toku’s AI-powered BioAge algorithm can be securely deployed in a large-scale clinical setting using BeeKeeperAI’s confidential computing technology and end-to-end encryption.AI technology is advancing at an unprecedented rate. Following best practices and implementing effective policy and safety measures are critical for successful deployment and containment of AI solutions. “Microsoft’s expertise in safe computing and AI provides a significant boost to our vendor-inclusive Harmony Network as a delivery environment for AI-powered decision support algorithms,” said Hideyuki Takizawa, Topcon Corporation, Senior Executive Officer, and Global Managing Director of the Eye Care Business division. www.topconhealthcare.com Additionally, the THI Corporate Venture Capital fund is enabling Healthcare from the Eye by investing in science-based AI innovators. “We are providing these AI partners funding, business consulting, and the ideal delivery platform to help accelerate commercialization of their AI solutions for healthcare,” said Fumio Ohue, SVP of Topcon Corporation and Chairman of THI.“Microsoft’s healthcare and AI expertise adds a powerful dimension to Topcon Healthcare’s vision to empower providers with smart and efficient technologies for enhanced patient care,” said Peter Durlach, Corporate Vice President, Chief Strategy Officer, Microsoft Health & Life Sciences. “With Microsoft Azure and the Precision Imaging Network, we provide the robust and secure cloud infrastructure essential for developing and deploying real-world applications at scale, integrated directly into provider workflows at the point of care.”About Topcon Healthcare, Inc.Topcon Healthcare, Inc. is part of Topcon Corporation (TSE 7732). Our vision is to improve access and quality of healthcare while decreasing the overall cost. To achieve this mission, we have established Harmony, a platform to accelerate the evolution of AI-powered algorithms that enable the detection of systemic, neurological, and ophthalmic disease markers even before discernable symptoms are present. Topcon Healthcare is investing in innovators focused on healthcare transformation with an emphasis on AI-powered digital Healthcare from the Eye. This approach helps doctors to prevent disease and, when needed, to treat at the earliest disease state for better, less costly outcomes.A truly global business, Topcon Corporation is focused on developing solutions to solve societal challenges in the mega-domains of healthcare, agriculture, and infrastructure. In healthcare, these challenges include increasing eye disease, rising medical costs, physician shortages, and unequal access to healthcare. By investing in value-driven innovations, Topcon Corporation works to help people enjoy good health and a better quality of life.
-
Announcing Exclusive Partnership with Espansione Group
Aimed at Driving Disruptive Innovation in Eye Care and Beyond in South-East AsiaTopcon Singapore Medical (referred to as “Topcon” in this document for brevity’s sake) and Espansione Group announce today a long-term exclusive partnership for the South-East Asia region.Starting April 1, 2023, Topcon will be the official and sole distributor for the South East Asian region of Espansione Group’s full portfolio, including light-based technologies such as Light Modulation® Low-level Light Therapy (LM® LLLT), its signature photobiomodulation technology, and Optimal Power Energy® Intense Pulsed Light (OPE® IPL).“We’re thrilled to grow our relationship with Topcon even stronger, including the South-East Asian region to our global collaboration efforts” commented Matteo Corbellino, Chief Marketing & Innovation Officer at Espansione Group. “We found a true partner in Topcon with a highly engaged and capable team striving to always deliver an extremely high level of service. We both want to raise the bar in the dry eye field and beyond, and that’s where we’ve found alignment. We believe that this partnership will create a powerful synergy that will enable us to push the boundaries of what’s possible in ophthalmology and beyond—as our technologies gain momentum worldwide, APAC and SEA in particular will be increasingly relevant for us.” “It's been Topcon Asia leadership's vision to look for ground-breaking type of collaborations. Our chance to meet the Espansione executive team gave us the opportunity to turn this vision into a reality” said Leo Nagatake, Managing Director at Topcon. “We see this strategic alliance with Espansione paving the way for our privileged access into their range of highly innovative and forward-thinking treatment products and solutions complementing the comprehensive range of Topcon's diagnostic equipment such as our MYAH - the unique multifunctional instrument for the management of dry eye & myopia. This synergistic partnership will further expand our service spectrum enabling us to provide more wholistic solutions to our esteemed clientele; from pre-diagnosis towards effective dry eye treatment followed by post treatment follow ups that will eventually benefit our end patients with a comprehensive end to end experience.”Professionals are encouraged to contact Topcon to obtain details on the portfolio of solutions in light therapy and digital imaging showcased with this partnership, including eye-light® , meibomask®, my-mask® and me-check®.About Espansione GroupEspansione Group is an established player in the medtech industry. Since 1981, Espansione Group has delivered the highest standard in the industry. Every day, the company invests heavily in researching and developing the Espansione Ecosystem to achieve its ambition: establishing new paradigms in ophthalmology and beyond, driven by its desire to provide its partners and their patients with the best, certified medical technologies, Light Modulation® Low-level Light Therapy (LM® LLLT) and Optimal Power Energy® Intense Pulsed Light (OPE® IPL). Present in over 50 countries, Espansione Group's aims to continue its strong growth in years to come, relentlessly focusing its efforts on research, development, and customer excellence. For more information, see www.espansionegroup.itAbout Topcon HealthcareTopcon Healthcare sees eye health differently. Our vision is to empower providers with smart and efficient technologies for enhanced patient care. Keeping pace with the ever-changing landscape of the healthcare industry, we offer the latest integrated solutions including advanced multi-modal imaging, vendor-neutral data management, safe distancing, and ground- breaking remote diagnostic technology.A globally-oriented business, Topcon is focused on developing solutions towards solving societal challenges in the mega-domains of healthcare, agriculture, and infrastructure. In healthcare, these challenges include increasing eye disease, rising medical costs, access to healthcare and physician shortages. By investing in value-driven innovations, Topcon works to enable people to enjoy good health and a high quality of life.For more information, see https://topconhealthcare.sgMedia ContactsEspansione GroupMatteo Corbellinomatteo.corbellino@espansione.itTopcon Singapore MedicalPatrick Foopfoo@topcon.com
-
Notice of Changes of President and CEO (Replacement of President)
January 30, 2023Topcon Corporation (TSE: 7732) hereby announces that the change of President and CEO was resolved at a meeting of the board of directors held today. The appointments will take effect on April 1, 2023.Change of President and CEO（effective April 1, 2023）NameNew PositionCurrent PositionSatoshi HiranoRepresentative Director,ChairmanRepresentative Director,President & CEOTakashi EtoRepresentative Director,President & CEORepresentative Director,Executive Vice PresidentGeneral Manager, Quality Assurance Div.Takashi EtoTopcon Corporation, the parent company of all Topcon Healthcare companies, announced changes in their president and CEO position that will be effective with the new fiscal year. Takashi Eto will assume the position of Representative Director, President and CEO, effective April 1, 2023. Current Topcon Corporation President and CEO Satoshi Hirano has served in the role since 2013 and will continue to contribute to the development of Topcon as Chairman of the Board, assisting and advising the new president.Read the news on the Topcon Corporation Website : link
-
Topcon Achieves ISO 27001 Certification of its Clinical Data Management Platform, Harmony
Published on January 24, 2023Topcon Healthcare has obtained ISO 27001 certification of its Clinical Data Management Platform, Harmony Referral System. ISO 27001 is a globally recognized standard for the establishment and certification of an information security management system (ISMS). The standard specifies the requirements for establishing, implementing, operating, monitoring, reviewing, maintaining and improving a documented ISMS within the context of the organization’s overall business risks. It sets forth a risk-based approach that focuses on adequate and proportionate security controls that protect information assets and gives confidence to interested parties.By achieving ISO 27001 certification for Harmony, Topcon has demonstrated that its newest robust data management application meets the most stringent requirements for data integrity, according to Topcon. The certification was performed by Schellman & Company.Harmony is a browser-based data management system that allows eye care providers to connect all of their diagnostic instruments, regardless of manufacturer, into one secure, web-based platform.Your Workflow Reimagined.Technology that drives clinical efficiency.HarmonyLEARN MORE
-
Topcon Introduces NW500 Non-Mydriatic Retinal Camera
TOKYO, JAPAN, OCTOBER 2022 – Topcon Healthcare, a leading provider of medical devices and software solutions for the global eye care community, is pleased to announce that it has launched the NW500, its new fully-automatic, non-mydriatic retinal camera that delivers reliable, sharp-quality imaging with enhanced capability.The NW500 offers innovative slit scan illumination and a rolling shutter mechanism, which helps to overcome one of the known causes of poorly graded images in its ability to effectively image smaller pupils, from 2.0mm or more*. A 12-megapixel sensor delivers excellent quality colour fundus images for clear review and analysis.The NW500 contributes to a streamlined workflow and enhanced patient experience by offering the ability to acquire retinal images in a lighted setting without the need to dilate patients. The NW500 offers excellent quality colour fundus images across the traditional 3 fixation points (Disc, Centre, and Macula), as well as the 9 fixation positions for peripheral photography.Touch-screen operation offers rapid, simple capture with just one touch. Fully-automated operation gives clinicians the flexibility to delegate screening to non-clinical staff. The improved processing speed** means it takes less time to capture images and gives operators the ability to increase patient throughput. A variety of connectivity options are available to suit the needs of clinical and screening businesses.“The NW500 reflects Topcon’s commitment to continuous innovation in pursuit of technology that helps to improve the quality-of-care patients receive and make care more efficient and accessible,” says Senior Director of Product Management, Tobias Kurzke. “Combined, the innovative slit scan technology and 12-megapixel camera offer clinicians fast, sharp quality imaging with less failure and retakes, making the process of acquiring fundus images faster and more reliable than before. The added benefit of enhancing the patient experience through faster screening times and the absence of the need for dilation will give clinicians and large volume wellness screening settings a competitive advantage.”Find out more about NW500https://topconhealthcare.jp/products/nw500/* Confirmed with model eye** As compared to the Topcon non-mydriatic retinal camera TRC-NW400Note: The information contained on this website is intended for healthcare professionals. Not all products, services or offers are approved or offered in every market, and products vary from one country to another. Contact your local distributor for country-specific information and availability.
-
Topcon Introduces SOLOS – Automatic Lens Analyzer
APRIL, 2022 - Topcon Healthcare, a leading provider of medical devices and software solutions for the global eye care community, is pleased to announce that it has launched SOLOS, an automatic lens analyzer that enables advanced, accurate and efficient lens analysis at the touch of a button, to Asia Pacific region.SOLOS simplifies clinical workflow by combining a fully automated lensmeter with a full range spectrometer. The multi-functional device offers automatic lens type detection, automatic marking, and lens mapping of single vision, progressive and other multifocal lenses, whether glazed in a spectacle frame or as uncut lenses. With a single touch, SOLOS automatically positions each lens, detects the lens type and performs comprehensive measurements of both lenses within a spectacle frame.SOLOS features an extended measurement range of +/- 20D and a built-in spectral transmittance meter that measures UV, blue & visible light transmittance as well as lens tint. Results are displayed instantly and can be sent to an EMR or wirelessly transferred to Topcon’s CV-5000S or Chronos refraction system, enhancing connectivity, preventing transcription errors, and enabling seamless comparisons of new prescriptions with previous spectacles to support purchasing decisions.“SOLOS goes beyond conventional lensometry and continues in Topcon’s tradition of developing smart, efficient and multimodal technologies that enhance patient care. As the name implies, one device does it all, enabling eyecare practitioners to benefit from increased operational efficiencies while obtaining highly accurate and comprehensive lens measurement results. We are very pleased to bring this device to market,” stated Paul op den Kelder, Global Product Manager for Topcon Healthcare.Find out more about SOLOShttps://topconhealthcare.jp/products/solos/Note: The information contained on this website is intended for healthcare professionals. Not all products, services or offers are approved or offered in every market, and products vary from one country to another. Contact your local distributor for country-specific information and availability.
-
The Market Leader in OCT & Data Management Joins Forces with AI Expert to Provide Improved Clinical Care
Topcon Healthcare of Oakland, NJ, a leading provider of medical devices and software solutions for the global eye care community, announced today that it will partner with RetInSight GmbH, a developer of retina AI solutions based in Vienna, Austria. The two companies aim to develop a seamless interface between RetInSight’s AI-assisted retinal biomarker applications and Topcon’s market-leading¹ OCT devices and cloud-based data management solution, Harmony.RetInSight’s novel, proprietary algorithms aim to support clinicians in the detection, quantification, and monitoring of key retinal biomarkers including retinal fluid and geographic atrophy lesions. With this collaboration, Topcon and RetInSight hope to extend retinal fluid detection and monitoring to primary eye care providers, facilitating comanagement of patients. In parallel, the two companies intend to develop and deploy automated, OCT-based screening and monitoring applications of geographic atrophy (GA), the leading cause for severe and irreversible visual loss. The availability of RetInSight’s novel OCT-based biomarker algorithms on Topcon’s solutions further augments the clinical utility and versatility of the workflow efficient Maestro2 Robotic OCT and the Triton Swept Source OCT. The cloud based Harmony data management system is known for its seamless connection to hundreds of ophthalmic devices across multiple practice locations to enable analysis of relevant clinical data in a single, secure platform. Harmony streamlines office workflow, allows for detailed analysis of clinical data, and integrates seamlessly with EMR software and will facilitate the deployment of RetInSight’s AI solutions without compromise of clinical efficiency.“Combining Topcon’s high quality imaging and data management with RetInSight’s novel AI application will lead to improved clinical decision making and efficient disease management. We are very pleased to add this powerful module to our already robust Harmony clinical data management solution and to our world-leading OCT’s,” said Tobias Kurzke, Director of Product Management for Topcon Healthcare.“RetInSight´s partnership with Topcon will facilitate access of AI-based solutions to primary eye care providers, elevating the standard of care by enabling early detection and accurate referrals to advanced eye care specialists for timely treatment of the major retinal diseases. RetInSight’s Clinical Decision Support System and Topcon’s global OCT and PACs footprint offers an unprecedented opportunity for co-management of patients with retinal diseases,” summarized Corinna zur Bonsen-Thomas, Chief Executive Officer of RetInSight.About RetInSight GmbHRetInSight is a digital health company developing transformational retinal AI solutions to improve patient outcomes, increase clinical efficiency and reduce healthcare costs. They empower eye care providers and professionals, academic institutions, and the eye care industry to reimagine clinical care with their extensive artificial intelligence solutions. RetInSight helps its partners leverage data to provide novel insights in unmet diagnostic needs associated with diseases that manifest in the retina. They have developed a comprehensive library of validated AI-algorithms for retinal biomarkers in systemic and retinal diseases, trained on extensive and continuously growing databases. Bringing together the most advanced technologies in computer science and state-of-the-art clinical expertise as well as medical science, they are set on shaping the future of digital precision medicine.1. As reported by Market Scope’s 2020 Ophthalmic Diagnostic Equipment Market Report.【Press release information in US】https://www.businesswire.com/news/home/20210803005991/en/Topcon-Healthcare-to-Partner-with-RetInSight
-
Topcon acquires VISIA Imaging S.r.l, ophthalmic medical device manufacturer in Italy
Tokyo, Japan – July 6th, 2021 - Topcon Corporation announced that it has acquired VISIA Imaging S.r.l, an ophthalmic device manufacturer headquartered in suburban Florence, Italy.VISIA Imaging S.r.l (hereinafter “VISIA”), was established in 1993 and specializes in the design, development, and manufacturing of anterior segment (cornea, crystalline lens, etc.) examination hardware and software. This acquisition enhances Topcon’s development and manufacturing capabilities of anterior segment devices and software, which complements the company’s strong portfolio of fundus imaging devices that includes fundus cameras and optical coherence tomography (OCT). The acquisition further reinforces Topcon’s position as a leading ophthalmic diagnostic device manufacturer.For many years, Topcon has been a distributor of VISIA’s technology including the CC-100 series visual acuity charts (CC-100 series), the CA-800 topographer and corneal analyzer, the MYAH biometer and corneal topographer and the Aladdin biometer. “The integration of a Japanese company and an Italian company, both with strengths in optical design, mechanical engineering, and manufacturing of medical devices, will enhance the synergies between the two companies. Both VISIA and Topcon value true reliability and innovative technology, making two companies ideal partners. I am very excited to move forward in our business together to continue producing advanced technology that benefits both patients and eye care professionals.””- commented Fumio Ohue, Managing Executive Officer of Topcon Corporations.Major VISIA products:(from the left: ALADDIN, CA-800, CC-100, MYAH)The acquisition of VISIA will enable Topcon to create additional synergies within the company’s product portfolio, expand its product offering, strengthen the Topcon Healthcare brand, and continue to grow the business. Furthermore, the acquisition gives Topcon Healthcare additional product design and development capabilities that will accelerate product development and enable the company to better meet the needs of the market.“I am so pleased that VISIA Imaging is becoming part of Topcon Healthcare and very excited for the next chapter in our long relationship. VISIA Imaging is focused on development and manufacturing of HW/SW solutions for eye care with high expertise in anterior segment. I am confident to release new beautiful products to support Topcon to become a market leader in myopia management, and to increase Topcon’s presence in cataract surgery with Premium IOL calculation”- said Alessandro Foggi, CEO VISIA Imaging S.r.lVISIA’s product portfolio helps eye care professionals diagnose and manage a number of eye health conditions including myopia. In recent years, the increase in the number of patients at risk for myopic-related eye diseases has become a global issue, and Topcon is committed to working with eye care professionals to address this eye health problem. By integrating VISIA and its products into the Topcon Healthcare portfolio, the company is better equipped to develop myopia management solutions and strengthen collaborations with companies in the myopia treatment field.[Press release information in Europe]https://www.businesswire.com/news/home/20210714005887/en/Topcon-Healthcare-Acquires-VISIA-Imaging
-
Topcon Announces the Launch of Chronos
It is time to reinvent refraction.Update January 28, 2021Topcon launches the revolutionary Chronos, Refraction System.Topcon, a leading provider of eye care devices and software solutions for the global eye care community, announced the launch of the revolutionary Refraction System, Chronos.Topcon Chronos offers binocular autorefraction, keratometry measurements and visual acuity with subjective testing. Chronos is the single space-saving instrument that optimizes the Eye Care Professionals’ workflow.SAVE SPACEChronos combines binocular autorefraction and keratometry measurements with binocular subjective testing and visual acuity in a single instrument that occupies minimum space.Chronos reduces the number of conventional refraction lanes and additional refractometers needed.GROWChronos offers the versatility critical for growing your practice.DELEGATESightPilot™ is a guided refraction system that simplifies the exam and facilitates delegation..list .wp-block-column { padding-left: 0;}.list .wp-block-column ul { padding-left: 20px;}.wp-block-columns+.wp-block-columns { margin-top: 20px;}@media (max-width: 781px) {.wp-block-columns+.wp-block-columns { margin-top: 40px;}}(press release information in Europe)https://kommunikasjon.ntb.no/pressemelding/topcon-announces-the-european-launch-of-chronos?publisherId=90063&releaseId=17896062(press release information in the U.S.)https://www.businesswire.com/news/home/20201113005598/en/Topcon-Announces-the-US-Launch-of-Chronos*About the Chronos, Refraction SystemAbout Topcon HealthcareTopcon Healthcare is a branded eyecare business of Topcon. Topcon Healthcare sees eye health differently. Our vision is to empower providers with smart and efficient technologies for enhanced patient care. Keeping pace with the ever-changing landscape of the healthcare industry, we offer the latest integrated solutions, including advanced multi-modal imaging, vendor-neutral data management, safe distancing, and ground-breaking remote diagnostic technology.
-
IDx and Topcon sign exclusive AI platform agreement for the U.S. market
IDx, the company behind the first and only FDA-cleared autonomous AI diagnostic system, joins forces with Topcon, a pioneering ophthalmic device manufacturer, to tackle preventable blindnessUpdate October 23, 2018CORALVILLE, IA and OAKLAND, NJ, October 22, 2018 - IDx, a leading AI diagnostics company, and Topcon, one of the world’s leading ophthalmic device manufacturers, have signed an exclusivity agreement that will allow the companies to scale delivery of AI-based diagnostic solutions in the U.S. market.The agreement grants exclusive rights to IDx in the U.S. as the only autonomous AI company permitted to sell its products with the Topcon NW400 - an easy to use, robotic fundus camera. Topcon continues to collaborate with other partners in the AI space for solutions that fall outside of this autonomous agreement.In turn, IDx has agreed to assign Topcon’s NW400 as the only robotic desktop fundus camera with less than a 55 degree field of view to be integrated with IDx-DR, an autonomous AI system that instantly detects diabetic retinopathy in fundus images.“The importance of ease of use and consistently high image quality to successfully implement autonomous AI diagnostics in the front lines of care cannot be stressed enough,” said Michael D. Abramoff, MD, PhD, founder and CEO of IDx. “Topcon is truly the innovative market leader in developing highly automated, consistent and easy to use retinal imaging systems. Together we can prevent visual loss and blindness by ensuring the safety, accessibility, and affordability of early disease detection.”Both companies have a history of innovation. IDx received FDA clearance for IDx-DR in April 2018, marking the first time the FDA has cleared an autonomous AI diagnostic system that does not require a physician to interpret images or results. Topcon introduced the first commercial back-of-the-eye spectral domain (SD) and swept source (SS) optical coherence tomography (OCT) systems and more recently announced the widely successful Maestro and Triton OCTs.“Our partnership with IDx further solidifies our position as a pioneer in the eye care business,” said Fumio Ohue, Managing Executive Officer of Topcon. “Our efforts to deliver better workflow solutions, imaging technology, and AI tools to eye care providers will be complemented by our work with IDx to bring autonomous diagnostics to a growing population of people with diabetes.”The recent FDA clearance of IDx-DR followed a clinical trial that demonstrated the autonomous AI system’s ability to safely deliver specialty-level diagnostics in primary care settings. Novice operators received minimal training on how to capture images using the Topcon NW400 and IDx-DR’s image quality AI. They successfully produced a diagnostic result 96% of the time by consistently capturing the high-quality images needed for IDx-DR to make a disease assessment.Topcon recently announced the release and class II clearance of Topcon Harmony, a diagnostic data management application with vendor-neutral connectivity that enables software providers like IDx, EHRs and third-party manufacturers to seamlessly integrate diagnostic results into one central location for eye care providers.About IDxIDx is a leading AI diagnostics company on a mission to transform the quality, accessibility, and affordability of healthcare. Founded in 2010 by a team of world-renowned clinician scientists, the company is focused on developing clinically-aligned autonomous algorithms that detect disease in medical images. By enabling diagnostic assessment in primary care settings, IDx aims to increase patient access to high-quality, affordable disease detection.The company’s first product, IDx-DR, is an FDA-cleared AI-based diagnostic system designed for use at the front lines of care to detect diabetic retinopathy. IDx-DR is intended for use by health care providers to automatically detect more than mild diabetic retinopathy in adults (22 years of age or older) diagnosed with diabetes who have not been previously diagnosed with diabetic retinopathy. IDx-DR is indicated for use with the Topcon NW400, an easy to use and highly accurate robotic fundus camera.IDx is developing additional AI-based diagnostic systems for the detection of macular degeneration, glaucoma, Alzheimer’s disease, cardiovascular disease, and stroke risk. Prior to this current round, IDx had been funded by a group of private angel investors since the company’s founding in 2010.About TopconTopcon is a comprehensive ophthalmic device manufacturer within the worldwide ophthalmic community. It introduced the world’s first commercial back-of-the-eye spectral domain (SD) and swept source (SS) optical coherence tomography (OCT) systems, which have driven innovation in eye-care.More recently, Topcon Healthcare Solutions started to enhance not only its hardware but also its software solutions. To become the leader in diagnostic software, Topcon has developed a new strategic division whose primary objective is to create world-class software solutions for the eye-care industry and beyond. The company’s products enable the collection and visualization of a wide range of imaging and clinical data while providing quantitative and clinical analysis capabilities.Topcon’s software gives clinicians access to patient exam data captured from OCTs, Visual Fields, Fundus cameras, and other Topcon and third-party devices. Topcon leverages its image management software called Synergy, where practitioners gain access to DICOM and non-DICOM information stored in a central, cloud-based environment. Additionally, Topcon now provides an integrated service that connects practitioners to an extensive network of reading services to assist in the management of sight-threatening eye diseases.IDx2300 Oakdale BlvdCoralville, IA 52241Phone: 319-248-5620www.eyediagnosis.net
-
Topcon acquires KIDE Clinical Systems, a leading optical and ophthalmology software provider
Acquisition combines the most advanced optical and ophthalmology cloud solution provider in the market with Topcon healthcare solutions - world leader in eye care technology industry.TOKYO, Japan - April 4, 2018 - Topcon Corporation announced that Topcon Healthcare Solutions, a subsidiary in the U.S., has acquired all the outstanding shares of KIDE Clinical Systems Oy, a recognized technology leader in optical and ophthalmology cloud solutions.KIDE Clinical Systems’ Optoflow, a digital imaging solution software, connects eye care devices to produce their data automatically to KIDE Cloud where hospital grade tools are provided for diagnostic work and telemedicine. The cloud enables digital, time and place independent workflow for optical chain and eye hospitals.Further on Topcon strengthens its position in Europe as KIDE Clinical Systems becomes its research and development center for eye care cloud solutions.“Cutting Edge data management cloud based solution is an important component for screening and prognostic management service.” commented by Akifumi Baba, the president of Topcon Healthcare Solutions. “Combining KIDE Clinical Systems’ modern technology with our strong hardware, we believe we can provide advanced solution to all eye care professionals and strength our position in eye care industry”.“We’re excited to join the Topcon family,” said Anssi Ylimaula, co-founder and CEO of KIDE Clinical Systems. “Combining Optoflow with Topcon devices will create something never seen in the medical imaging market before. With Topcon sales and financial resources we can give our customers significant leverage in their own business.”“We’ve spent the last few months with the Topcon team harmonizing and honing our joint strategy. We are excited to be bringing these technological advances to the healthcare industry as part of the Topcon team,” said Ylimaula.
You are visiting TopconHealthcare APAC.
If you are looking for different region, please select "Go to Contact Us".